Exploiting the elevated mitotic activity and cholesterol demand of cancer cells, these LDL-like nanoemulsions—devoid of protein yet capable of acquiring apolipoproteins such as apo E from plasma—leverage the endocytic pathway mediated by LDL receptors for cellular uptake3,4. The gene discussed is LDLR; the disease is cancer.